Skip to NavigationSkip to content

Roche's Tecentriq+chemo boosts survival in first-line non-small cell lung cancer

Published on 22/10/18 at 11:59am

Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society for Medical Oncology (ESMO) 2018 Congress, with the Swiss pharma firm presenting new findings supporting the use of Tecentriq (atezolizumab) in combination with chemotherapy in the first-line treatment of previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC).

When paired with carboplatin and Abraxane chemo, Roche’s data showed that the combo allowed patients to live “significantly longer” lives, extending median overall survival by 18.6 months compared to 13.9 months for chemotherapy alone, and also improved progression-free survival rate by 7 months as opposed to 5.5. The safety profile of the drug was also found to be consistent with previous studies, with no new safety signals reported.

“Initial treatment with this Tecentriq-based combination provided a significant survival benefit for people with non-squamous non-small cell lung cancer, the most common form of lung cancer,” remarked Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “Lung cancer is a complex disease and this combination could offer a new potential treatment option. We will work with global health authorities to bring this regimen to people living with this disease as soon as possible.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches